ANX Mast Therapeutics, Inc.

SAN DIEGO, Dec. 1 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) today announced that Brian M. Culley, vice president of business development, will present a corporate overview at the Informed Investors Bay Area Biotechnology and Healthcare Forum on Wednesday, December 7th at 9:40 am PST, at The Hyatt Regency in San Francisco. For more information about this conference and to access a live slide and audio webcast of Mr. Culley's presentation, visit http://www.investorcalendar.com/IIF/CustomEvent/90563/index.asp. Presentations from the forum will be archived at http://www.investorcalendar.com/IIF/CustomEvent/90563/index.asp. About ADVENTRX ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on introducing new technologies for anticancer and antiviral treatments that improve the performance and safety of existing drugs by addressing significant problems such as drug metabolism, toxicity, bioavailability and resistance. The Company's lead compound, CoFactor(TM), is a biomodulator of 5-fluorouracil (5-FU), a widely used cancer chemotherapy agent. Phase II and Phase IIb clinical trials are ongoing to evaluate CoFactor use with 5-FU as a first line treatment of metastatic colorectal cancer. The Company has received clearance under a special protocol assessment from the US Food and Drug Administration (FDA) to begin a CoFactor Phase III pivotal clinical trial for metastatic colorectal cancer, which is currently planned to begin patient dosing in Q1 2006. More information can be found on the Company's Web site at http://www.adventrx.com/. Forward Looking Statement This press release contains forward-looking statements, within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, regarding ADVENTRX. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the FDA and other regulatory agencies. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements regarding ADVENTRX, see the section titled "Risk Factors" in ADVENTRX's last quarterly report on Form 10-Q, as well as other reports that ADVENTRX files from time to time with the Securities and Exchange Commission. All forward-looking statements regarding ADVENTRX are qualified in their entirety by this cautionary statement. ADVENTRX undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof. DATASOURCE: ADVENTRX Pharmaceuticals, Inc. CONTACT: Andrea Lynn of ADVENTRX Pharmaceuticals, +1-858-552-0866 Web site: http://www.investorcalendar.com/IIF/CustomEvent/90563/index.asp http://www.adventrx.com/ Company News On-Call: http://www.prnewswire.com/comp/920134.html

Copyright